Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial
Author/s
author: Richard Scolyer, Michel W Wouters, Georgina V. Long, Kerwin F Shannon, Dirk J Grünhagen, Ellen Kapiteijn, Geke A P Hospers, Alexander C.J. van Akkooi, Karijn P. Suijkerbuijk, John B A G Haanen, Christian U Blank, Sydney Ch'ng, Robyn Saw, Joris B W Elbers
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.